ClinicalTrials.gg

Program

ocankitug

Also written as “CM326”, “CM326(formulation 1)” and “CM326(formulation 2)”.

Its studies are mostly in Asthma · Nasal Polyps · Dermatitis, Atopic · Pulmonary Disease, Chronic Obstructive, led by 2 companies.

Furthest: phase 3, since Dec 13, 202113 company-led studies, 5 open or runningNext primary completion: Jul 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keymed Biosciences81 open or runningphase 2since Dec 13, 2021Apr 8, 2021none ahead
CSPC Pharmaceutical Group54 open or runningphase 3since Jan 11, 2026Mar 6, 2023Jul 1, 2027phase 2 · NCT07418736
  • Named in CSPC Pharmaceutical Group’s own pipeline as CM326, phase 3, as of Aug 20, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 8, 2021First study: phase 1 study in AsthmaNew to Keymed BiosciencesKeymed Biosciences · NCT04842201 · 44 enrolled · China
  2. Dec 9, 2021Phase 1 study in AsthmaKeymed Biosciences · NCT05171348 · 40 enrolled · China
  3. Dec 13, 2021Phase 2 study in Moderate-to-severe Atopic DermatitisKeymed Biosciences · NCT05186922 · 54 enrolled · China
  4. Mar 18, 2022Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsKeymed Biosciences · NCT05324137 · 88 enrolled · China
  5. Dec 26, 20222 phase 2 studiesKeymed Biosciences · NCT05671445, NCT05671432
  6. Jan 27, 2023Phase 1 study in HealthyKeymed Biosciences · NCT05715333 · 46 enrolled · China
  7. Mar 6, 2023CSPC Pharmaceutical Group's first study: phase 2 study in Moderate to Severe AsthmaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT05774340 · 207 enrolled · China
  8. Apr 15, 2024Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsKeymed Biosciences · NCT06372678 · 90 planned · China
  9. Jan 11, 2026Phase 3 study in Moderate to Severe AsthmaPhase 3 reachedCSPC Pharmaceutical Group · NCT07372287 · 230 planned · China
  10. Feb 4, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveCSPC Pharmaceutical Group · NCT07418736 · 318 planned · China
  11. Feb 12, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsCSPC Pharmaceutical Group · NCT07420257 · 212 planned
  12. Apr 14, 2026Phase 1 study in Healthy SubjectsCSPC Pharmaceutical Group · NCT07560033 · 192 planned

Ahead

  1. Jul 1, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveCSPC Pharmaceutical Group · NCT07418736
  2. Oct 30, 2028Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsCSPC Pharmaceutical Group · NCT07420257
  3. Dec 31, 2028Primary completion: phase 3 study in Moderate to Severe AsthmaCSPC Pharmaceutical Group · NCT07372287

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07560033Healthy Subjects1Not yet recruitingCSPC Pharmaceutical GroupOct 1, 2026192
NCT07420257Chronic Rhinosinusitis With Nasal Polyps3Not yet recruitingCSPC Pharmaceutical GroupOct 30, 2028212
NCT07418736Pulmonary Disease, Chronic Obstructive · China2RecruitingCSPC Pharmaceutical GroupJul 1, 2027318
NCT07372287Moderate to Severe Asthma · China3RecruitingCSPC Pharmaceutical GroupDec 31, 2028230
NCT06372678Chronic Rhinosinusitis With Nasal Polyps · China2Not yet recruitingKeymed BiosciencesJun 30, 202690
NCT05774340Moderate to Severe Asthma · China2UNKNOWNCSPC Pharmaceutical GroupJan 2025207
NCT05715333Healthy · China1CompletedKeymed BiosciencesOct 4, 202346
NCT05671445Dermatitis, Atopic · China2UNKNOWNKeymed BiosciencesMar 28, 2024100
NCT05671432Moderate-to-severe Atopic Dermatitis · China2UNKNOWNKeymed BiosciencesDec 30, 2023240
NCT05324137Chronic Rhinosinusitis With Nasal Polyps · China2CompletedKeymed BiosciencesMar 29, 202488
NCT05186922Moderate-to-severe Atopic Dermatitis · China2UNKNOWNKeymed BiosciencesJan 202354
NCT05171348Asthma · China1CompletedKeymed BiosciencesOct 11, 202240
NCT04842201Asthma · China1CompletedKeymed BiosciencesSep 28, 202144

How it is read

Names in the registry

  • “CM326”, 10 entries
  • “CM326(formulation 1)”, 1 entry
  • “CM326(formulation 2)”, 1 entry
  • “CM326 injection”, 1 entry
  • “CM326 dose 1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.